I
Irina Babina
Dr Irina Babina (PhD, MBA) is CEO of Concr, a UK TechBio company using astrophysics-based digital twins to predict cancer treatment response.
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
Sep 22, 2026
Getting predictive technologies to patients, with Concr
5:50
9:02

Nicole RaleighHOST
So if we think now about the digital factor here, what role can digital twins play here, Irina? So
I
5:58Irina BabinaGUEST
digital twins is a concept that has been used in other industries for a very long time, which means it's a computational simulation of a physical system and you can run multiple simulations and multiple scenarios before you realise it in the physical world.
I
6:15Irina BabinaGUEST
And engineering and aerospace engineering in particular is where it's been used for a very long time.
I
6:21Irina BabinaGUEST
In medicine, we have actually been adopting it for a while with processes and with different other systems, but it hadn't quite penetrated biology because inherently we don't understand biology.
I
6:38Irina BabinaGUEST
All the data about cancer is highly fragmented and it's all over the place in different formats.

Nicole RaleighHOST
I mean, with this or these regulatory issues remaining, what additional hurdles alongside that consideration of those frameworks remain, Irina?
Digital Controls for Cancer Drug Trials? Irina Babina, Concr
I
1:04Irina BabinaGUEST
We generate different types of data, and each one of these data sets kind of carries, uh, a little bit of information about biological state.
I
1:13Irina BabinaGUEST
But integrating all of that knowledge together is a challenge because these are really disparate data sets.
I
1:23Irina BabinaGUEST
So to actually be able to integrate and share learnings from all these data sets together in order to get a more complete picture of cancer biology has been challenging with, uh, conventional bioinformatics approaches and conventional data, um, analytics until recently, of course, where we can do a lot of da-data processing really quickly.